Navigation Links
Metamark Genetics Partners with Definiens on Tissue-Based Cancer Diagnostics
Date:6/30/2011

CAMBRIDGE, Mass. and MUNICH, June 30, 2011 /PRNewswire/ -- Metamark Genetics, a privately-held oncology molecular diagnostic company, and Definiens, the leading Health Image Intelligence™ company, today announced a development and commercialization partnership in which Metamark will combine its proprietary multiplex protein detection platform with image analysis technology developed jointly with Definiens to deliver innovative prognostic and predictive assays for early-stage cancers.

"Definiens is a clear world leader in quantitative digital pathology and in the analysis of biomarkers in tissue image data," said Eric Devroe, Ph.D., Vice President of Business & Strategy Development for Metamark. "We see great synergy in combining Definiens' technology and expertise with Metamark's unique understanding of tumor heterogeneity and insight into the molecular drivers regulating tumor formation and aggression. We believe that this partnership will enable us to co-develop and implement unique and important image analysis tools."

Metamark's quantitative diagnostic approach can identify and account for small regions of molecularly aggressive cancer cells within an otherwise indolent tumor. The company is developing a portfolio of prognostic and predictive assays with the ability to address the "heterogeneous" nature of tumors not only between one patient and the next, but also within an individual patient's tumor.

Definiens has made ground-breaking achievements in the field of biomarker development based on its highly robust and scalable image analysis framework that enables scientists and clinicians to rapidly extract comprehensive biomarker and morphology expression profiles and to identify a relevant subset of descriptors by correlating them against patient outcomes.

"Definiens is pleased to partner with Metamark Genetics, and to incorporate our image and data analysis software technology into Metamark's pioneering Oncology diagnostic offerings," said Thomas Colarusso, Vice President of Sales & Operations for Definiens Inc. "The capability to provide detailed readouts from tissue analysis is opening up new gateways for developing diagnostic assays as we enter the age of personalized medicine. We believe the Definiens Developer XD and Tissue Studio software will enable Metamark to classify tumor heterogeneity of multiplexed tissue stains and derive prognostic and predictive assays."

About Metamark Genetics, Inc.

Metamark is a privately held oncology company focused on the development of function-based prognostic assays for early staged cancers. The MetamarkDx™ Prognostic Assays under development are based on Metamark's proprietary Prognosis Determinants™, genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread. For further information, please visit the company's website at www.metamarkgenetics.com.

About Definiens

Definiens is a leading Health Image Intelligence™ company that develops software solutions for biomedical image analysis, data mining and clinical decision support. The company's software analyzes images from cell-based assays, whole tissue slides and full body scans and allows users to correlate this information with data derived from other sources, supporting better decisions in research, diagnostics and therapy. By automating analysis workflows and generating new knowledge, Definiens provides pharmaceutical and biotechnology companies, research institutions, clinical service organizations and medical professionals with deeper insights, faster results and better decision support. Harnessing the power of image intelligence, Definiens supports personalized medicine and aims to significantly improve the quality of patients' lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States. Further information is available at www.definiens.com.

Press Contacts:
Metamark Genetics, Inc.
Mark R. Straley
President & CEO
mstraley@metamarkgenetics.com
617-583-1422

Definiens, Inc.
Dr. Martin Baatz
Vice President Marketing
mbaatz@definiens.com


'/>"/>
SOURCE Definiens
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signal Genetics and DiagnoCure Announce a US$13.3M Collaboration for the Commercialization of Previstage™ GCC Colorectal Cancer Staging Test
2. Research 2.0 Updates Coverage of Viral Genetics with Research Report Focused on VG Energy
3. Viral Genetics Updates HIV/AIDS and Drug Resistant Cancer Research Programs
4. Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
5. USP Hospitales of Spain to Offer Interleukin Genetics Heart Health Test Throughout Its Hospital Network
6. Interleukin Genetics and Metagenics Initiate Research Collaboration
7. Technology Collaboration Between New England Biolabs and Sequenom Delivers First Product for Epigenetics
8. LABS, Inc. Announces Alliance with Ambry Genetics to Expand Testing Solutions for the Reproductive Health Industry
9. RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis
10. JS Genetics Develops New Non-Invasive Test, XCAT-TS, to Help Doctors Diagnose Turner Syndrome
11. Viral Genetics Researcher and Advisor Set to Share Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... British Columbia, March 27, 2017  Sophiris Bio ... or "Sophiris"), a clinical late-stage biopharmaceutical company developing ... urological diseases, today reported fourth quarter and full ... Key Corporate Highlights: ... Localized Prostate Cancer. During 2016, the Company reported ...
(Date:3/27/2017)... 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus ... Invictus MD is pleased to announce it has received ... on the TSX Venture Exchange.  Receiving ... year of significant achievements for Invictus-MD. Some of which ... at AB Laboratories Inc. ("AB Labs"), a Licensed Producer ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder ... few medical professionals in the country to sit on the 2017 National Advisory Board ... just 2 years Dr. Harper helped propel the clinic from a small start-up to ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Public relations pros ... across a variety of business channels. , While many results are clear, much of ... relations program. , When it comes to measurement, firms should always take an ...
(Date:3/28/2017)... ... , ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders ... offer to the discussion of dealing with excess skin oil. “Oily skin is a challenge ... that can help remove the oily shine while keeping the skin fresh and clean,” says ...
(Date:3/28/2017)... California (PRWEB) , ... March 28, 2017 , ... Bacteria and fungi are probably not ... microorganisms are bad. In fact, including the right microorganisms in your diet can actually improve ... favorite foods. , This is the topic of a new peer-reviewed paper ...
(Date:3/27/2017)... ... 2017 , ... New patients who want to experience the benefits of ... them placed by Dr. Manju Kejriwal, with or without a referral. Dr. Kejriwal is ... accuracy of each dental implant placement. The i-CAT CBCT system captures the shapes of ...
Breaking Medicine News(10 mins):